Cargando…

Five lipoxygenase hypomethylation mediates the homocysteine effect on Alzheimer’s phenotype

Environmental and genetic risk factors are implicated in the pathogenesis of Alzheimer’s disease (AD). However, how they interact and influence its pathogenesis remains to be investigated. High level of homocysteine (Hcy) is an AD risk factor and associates with an up-regulation of the ALOX5 gene. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jian-Guo, Barrero, Carlos, Merali, Salim, Praticò, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382538/
https://www.ncbi.nlm.nih.gov/pubmed/28383037
http://dx.doi.org/10.1038/srep46002
_version_ 1782520121082773504
author Li, Jian-Guo
Barrero, Carlos
Merali, Salim
Praticò, Domenico
author_facet Li, Jian-Guo
Barrero, Carlos
Merali, Salim
Praticò, Domenico
author_sort Li, Jian-Guo
collection PubMed
description Environmental and genetic risk factors are implicated in the pathogenesis of Alzheimer’s disease (AD). However, how they interact and influence its pathogenesis remains to be investigated. High level of homocysteine (Hcy) is an AD risk factor and associates with an up-regulation of the ALOX5 gene. In the current paper we investigated whether this activation is responsible for the Hcy effect on the AD phenotype and the mechanisms involved. Triple transgenic mice were randomized to receive regular chow diet, a diet deficient in folate and B vitamins (Diet), which results in high Hcy, or the Diet plus zileuton, a specific ALOX5 inhibitor, for 7 months. Compared with controls, Diet-fed mice had a significant increase in Hcy levels, memory and learning deficits, up-regulation of the ALOX5 pathway, increased Aβ levels, tau phosphorylation, and synaptic pathology, which were absent in mice treated with zileuton. In vivo and vitro studies demonstrated that the mechanism responsible was the hypomethylation of the ALOX5 promoter. Our findings demonstrate that the up-regulation of the ALOX5 is responsible for the Hcy-dependent worsening of the AD phenotype in a relevant mouse model of the disease. The discovery of this previously unknown cross-talk between these two pathways could afford novel therapeutic opportunities for treating or halting AD.
format Online
Article
Text
id pubmed-5382538
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-53825382017-04-10 Five lipoxygenase hypomethylation mediates the homocysteine effect on Alzheimer’s phenotype Li, Jian-Guo Barrero, Carlos Merali, Salim Praticò, Domenico Sci Rep Article Environmental and genetic risk factors are implicated in the pathogenesis of Alzheimer’s disease (AD). However, how they interact and influence its pathogenesis remains to be investigated. High level of homocysteine (Hcy) is an AD risk factor and associates with an up-regulation of the ALOX5 gene. In the current paper we investigated whether this activation is responsible for the Hcy effect on the AD phenotype and the mechanisms involved. Triple transgenic mice were randomized to receive regular chow diet, a diet deficient in folate and B vitamins (Diet), which results in high Hcy, or the Diet plus zileuton, a specific ALOX5 inhibitor, for 7 months. Compared with controls, Diet-fed mice had a significant increase in Hcy levels, memory and learning deficits, up-regulation of the ALOX5 pathway, increased Aβ levels, tau phosphorylation, and synaptic pathology, which were absent in mice treated with zileuton. In vivo and vitro studies demonstrated that the mechanism responsible was the hypomethylation of the ALOX5 promoter. Our findings demonstrate that the up-regulation of the ALOX5 is responsible for the Hcy-dependent worsening of the AD phenotype in a relevant mouse model of the disease. The discovery of this previously unknown cross-talk between these two pathways could afford novel therapeutic opportunities for treating or halting AD. Nature Publishing Group 2017-04-06 /pmc/articles/PMC5382538/ /pubmed/28383037 http://dx.doi.org/10.1038/srep46002 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Li, Jian-Guo
Barrero, Carlos
Merali, Salim
Praticò, Domenico
Five lipoxygenase hypomethylation mediates the homocysteine effect on Alzheimer’s phenotype
title Five lipoxygenase hypomethylation mediates the homocysteine effect on Alzheimer’s phenotype
title_full Five lipoxygenase hypomethylation mediates the homocysteine effect on Alzheimer’s phenotype
title_fullStr Five lipoxygenase hypomethylation mediates the homocysteine effect on Alzheimer’s phenotype
title_full_unstemmed Five lipoxygenase hypomethylation mediates the homocysteine effect on Alzheimer’s phenotype
title_short Five lipoxygenase hypomethylation mediates the homocysteine effect on Alzheimer’s phenotype
title_sort five lipoxygenase hypomethylation mediates the homocysteine effect on alzheimer’s phenotype
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382538/
https://www.ncbi.nlm.nih.gov/pubmed/28383037
http://dx.doi.org/10.1038/srep46002
work_keys_str_mv AT lijianguo fivelipoxygenasehypomethylationmediatesthehomocysteineeffectonalzheimersphenotype
AT barrerocarlos fivelipoxygenasehypomethylationmediatesthehomocysteineeffectonalzheimersphenotype
AT meralisalim fivelipoxygenasehypomethylationmediatesthehomocysteineeffectonalzheimersphenotype
AT praticodomenico fivelipoxygenasehypomethylationmediatesthehomocysteineeffectonalzheimersphenotype